Innovative targeted therapies have demonstrated progression-free and overall survival benefit for HER2 positive metastatic Breast Cancer (mBC). However, this disease still has a significant impact on patients’ lives. HERmione is a declarative crossed-view survey conducted among patients living with HER2 positive mBC and oncologists, to identify patients' unmet needs, and to better understand their experiences and perceptions of treatments to provide solutions.
Between July and October 2022, a total of 273 patients living with HER2-positive mBC have participated online to this survey via the Patient Advocacy Group “Mon Réseau Cancer du Sein” intranet, and a web based application developed by Wefight. Answers were also collected via the Steering Committee member by submitting a survey directly to their patients. Furthermore, 40 oncologists treating these types of cancers were asked some of these questions to provide a crossed-view survey.
The survey reveals a significant impact of the disease on patient Quality of Life (QoL), both on physical and mental health[1]. While the disease has a strong impact on QoL, results showed that nursing support is not systematic. Barely 40% of patients reported being accompanied by a nurse. A comparative analysis showed a significant impact of this support on their level of information and their sense of proximity with healthcare teams. Meanwhile, patients also express clear expectations regarding therapeutic innovations. Oral treatments are perceived as having more advantages than injectable ones, primarily because they allow patients to avoid time-consuming trips to healthcare facilities (76%). On the other hand, 46% of patients perceive oral treatments as reducing interactions with medical teams.
HERmione allowed to identify the patients ‘journey unmet needs. While this disease has significant impacts on their QoL, better support, particularly by nurses, would allow to enhance disease experience. HERmione also shows that patients are attached to the oral route, allowing a greater autonomy. Patients' involvement in treatment decisions as well as the support they receive are key factors that can influence their therapeutic evolution.
Wefight.
Seagen.
C. Rigault: Financial Interests, Personal and Institutional, Invited Speaker: Pfizer, Lilly. G. Freyer: Financial Interests, Personal and Institutional, Invited Speaker: Seagen, Roche, AstraZeneca, Pfizer, Novartis, GSK, MSD, BMS, Daiichi Sankyo, Lilly. All other authors have declared no conflicts of interest.